PMEF
TRDA icon

Point72 Middle East FZE’s Entrada Therapeutics TRDA Stock Holding History

Point72 Middle East FZE’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,441
Closed -$49.9K – 2060
2023
Q1 		$49.9K Buy
+3,441
New +$45.9K ﹤0.01% 1272

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Point72 Middle East FZE's TRDA Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Entrada Therapeutics (TRDA) in Q2 2023, closing a stake of 3,441 shares — an estimated $49.9K sold.

Point72 Middle East FZE first reported a position in TRDA in Q1 2023 and held it in 1 quarter. The position peaked at $49.9K in Q1 2023. 56 funds tracked by Wall St. Rank hold TRDA as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Entrada Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 3,441 Entrada Therapeutics shares in Q2 2023, an estimated $49.9K.
  • Point72 Middle East FZE first reported a position in Entrada Therapeutics in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Entrada Therapeutics position peaked at $49.9K in Q1 2023.
  • 56 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.